Advisory Committee Sides With FDA: King/Acura's Acurox Fails To Prevent Abuse
This article was originally published in The Pink Sheet Daily
Executive Summary
The public forum did no favors for Acurox, as advisory committee members questioned whether adding niacin to oxycodone would really deter abuse.
You may also be interested in...
Brand And Generic Opioid Makers Agree: FDA Should Issue Guidance On Tamper Resistance
But Purdue and Teva disagree on the key question of whether a generic of a tamper-resistant analgesic must have the same dosage form as the reference-listed brand-name drug.
Pfizer Will Study Oxecta Abuse/Misuse Potential Post-Market
FDA okays the opioid, which contains abuse-resistant components, with labeling about a study that found the drug less likeable than immediate-release oxycodone.
Pfizer Will Study Oxecta Abuse/Misuse Potential Post-Market
FDA okays the opioid, which contains abuse-resistant components, with labeling about a study that found the drug less likeable than immediate-release oxycodone.